A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II.

  title={A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II.},
  author={F. H. Degenring and Andy Suter and M. Weber and Reinhard Saller},
  journal={Phytomedicine : international journal of phytotherapy and phytopharmacology},
  volume={10 5},
A placebo controlled, randomised, parallel group, multicentre trial conducted in accordance with the guidelines of Good Clinical Practice (GCP) shows the efficacy and safety of a standardised extract of fresh berries of Crataegus oxyacantha L. and monogyna Jacq. (Crataegisan) in patients with cardiac failure NYHA class II. A total of 143 patients (72 men, 71 women, mean age of 64.8 (8.0 years) were recruited and treated with 3 times 30 drops of the extract (n = 69) or placebo (n = 74) for 8… 

Figures and Tables from this paper

Hawthorn extract for treating chronic heart failure.

There is a significant benefit in symptom control and physiologic outcomes from hawthorn extract as an adjunctive treatment for chronic heart failure according to double-blind randomised clinical trials.

Health effects of hawthorn.

Hawthorn medicinal extract has long been a favored herbal remedy in Europe, and its active components are thought to be flavonoids and oligomeric procyanidins.

Effect of Crataegus Usage in Cardiovascular Disease Prevention: An Evidence-Based Approach

The underlying pharmacology mechanisms in potential cardioprotective effects are discussed and the clinical applications of Crataegus and its various extracts are elucidated.

The genotoxic effects of fruit extract of Crataegus oxyacantha (hawthorn) in mice

Under experimental conditions, C. oxyacantha fruits extract exhibited weak clastogenic and/or aneugenic effects in bone marrow cells of male mice, confirming the previous in vitro findings that this plant extract induced genotoxicity suggesting that prolonged or high dose use needs to be undertaken with caution.

Adverse-Event Profile of Crataegus Spp.

All data reviewed in this article seem to indicate that hawthorn is well tolerated even if some severe adverse events were reported; this suggests that further studies are needed to better assess the safety of hawthORN-containing preparations.

Therapeutic efficacy of crategus oxyacantha L. For treatment of heart diseases: a cross-sectional study

Crataegus oxyacantha L. acts as a heart tonic and is best used in the form of mother tincture probably due to its flavonoids content and diversity in mechanism of action.

Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease

Current research to date suggests that hawthorn may potentially represent a safe, effective, nontoxic agent in the treatment of CVD and ischemic heart disease (IHD).

Hypolipidemic and cardioprotective benefits of a novel fireberry hawthorn fruit extract in the JCR:LA-cp rodent model of dyslipidemia and cardiac dysfunction.

It is demonstrated that both of the Canadian-sourced hawthorn extracts (introduced leaf and native berry) have cardioprotective benefits, likely via increased availability of nitric oxide.

Integrating supplementation in the management of patients with heart failure: an evidence-based review

Advances in large scale, randomized, placebo-controlled trials are necessary to support evidence-based decision making regarding the use of supplements in conjunction, and in comparison, to conventional therapies for heart failure.



[Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure].

The present study proves the efficacy and safety of a standardized extract of fresh Crataegus berries (Rob 10) in patients with congestive heart failure (NYHA II) regarding the parameters evaluated.

Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II.

The data show that Crataegus extract WS ® 1442 is clinically effective in patients with congestive heart failure corresponding to NYHA class II and was safe and well tolerated.

[Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study].

The active substance group showed a statistically significant advantage over placebo in terms of changes in PRP and the score, but also in the secondary parameter heart rate, and systolic and diastolic blood pressure was mildly reduced.

Efficacy of the Hawthorn (Crataegus) preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II.

Prognostic value of treadmill exercise testing: a population-based study in Olmsted County, Minnesota.

Exercise capacity was the TMET variable that exhibited the strongest association with all-cause mortality and cardiac events in this population-based cohort, and a protective effect of exercise capacity was observed in both sexes.

Crataegus-Extrakt hilft dem Patienten mit NYHAII

  • Herzinsuffizienz Therapiewoche
  • 1989